Skip to main content

Gene Therapy for Phenylketonuria: Homology & Biomarin Race to Bring Single Dose Treatment To Market

Phenylketonuria 

Phenylketonuria (PKU) is a genetic disorder of liver metabolism that arises primarily from the loss of function mutation of PAH gene encoding the hepatic enzyme phenylalanine (Phe) hydroxylase (PAH). Enzyme PAH converts Phe to produce tyrosine (Tyr) and subsequently funneled into other metabolic pathways.  
Lack of functional PAH results in hyperphenylalaninemia after dietary intake of protein, causing elevated systemic Phe levels. In high levels of Phe, patients show neurocognitive impairment and behavior problems. The classical PKU results in progressive, irreversible neurological impairment during infancy and early childhood, if left untreated. The characteristic features of the PKU include hypopigmentation in skin, hair, and eyes; eczema; growth retardation; and a mousy odor caused by the accumulation of phenylacetate and phenyllactate.


Market Analysis of PKU

The global phenylketonuria treatment market size was valued at USD 445.8 million in 2018 and is expected to register a CAGR of 11.0% from 2019 to 2026. The increasing prevalence of PKU across the globe is estimated to accelerate market growth. According to the Genetics Home Reference, 1 in 10,000 to 15,000 cases of PKU occurs in newborns in the U.S. In Europe, some countries have a high incidence rate of PKU, such as 1 in every 4500 babies in Ireland and 1 in 4,000 of individuals in Turkey, are suffering from the target disease.

Gene Therapy Approach

The investigation gene therapy is intended to deliver the PAH cDNA into the liver tissue of PAH deficient subject. The PAH transgene may produce sufficient PAH enzyme into the target tissue and normalize the Phe level.

Homology Medicine AAVHSC-15 PAH for treatment of PKU

HMI 102 is an investigational gene therapy intended to integrate the gene for the functional copy of PAH into the liver cells. The clinical study is being conducted to evaluate the safety and efficacy of HMI-102 gene therapy in adult subjects with PKU due to PAH deficiency. Subjects will receive a single dose of HMI-102 administered intravenously. (Learn More)

Biomarin AAV5-PAH for treatment of PKU

BMN-307 is an investigational gene transfer therapy intended to deliver its phenylalanine hydroxylase (PAH) gene to the liver tissue for the production of PAH enzyme protein. Biomarin is conducting a Phase 1/2 clinical trial (PHEARLESS) to evaluate the safety and efficacy of AAV-PAH gene therapy in subjects with PKU. (Learn More)

Sangamo Therapeutics: Sangamo's PKU gene therapy is at preclinical stage, therefore not covered. 






RTX-134, SYNB1618, and CNSA-001

Reference
www.biomarin.com
www.homologymedicines.com
https://www.grandviewresearch.com/industry-analysis/phenylketonuria-pku-treatment-market#:~:text=Industry%20Insights,estimated%20to%20accelerate%20market%20growth.

Labels:

Comments

Post a Comment

Popular posts from this blog

Carbohydrate Metabolism: MCQs and answers on Glycolysis & Gluconeogenesis

                                      MCQ on Glycolysis & Gluconeogenesis 1) Which of the following enzyme is not involved in galactose metabolism? a) Glucokinase b) Galactokinase c) Galactose-1-Phosphate Uridyl transferase d) UDP-Galactose 4- epimerase 2) Which of the following enzyme is defective in galactosemia (type I) - a fatal genetic disorder in infants? a) Glucokinase b) Galactokinase c) Galactose-1-Phosphate Uridyl transferase d) UDP-Galactose 4- epimerase 3) In the liver, the accumulation of which of the following metabolite attenuates the inhibitory of ATP on phosphofructokinase? a) Glucose-6-Phosphate b) Citrate c) Fructose-1,6-Bisphosphate d) Fructose-2,6-Bisphosphate 4) Mutation in which of the following enzymes leads to a glycogen storage disease known as "Tarui’s disease"? a) Glucokinase b) Phosphofructokinase c) Phosphoglucomutase d) Pyruvate Kinase 5) E...
Read More

MCQs and Answers on cultivation (culture/incubation), Isolation and Identification of microorganisms: Medical Microbiology

40 plus questions - Multiple Choice Questions on Classification, Culture, and Identification of the microorganisms 1. Which of the following microorganism has the cocci cell shapes and sizes arranged usually in tetrad structures? a)  Streptococcus pneumoniae b)  Staphylococcus aureus c)  Chlamydia trachomatis d)  Neisseria meningitidis 2. What are the different growth morphology and cell structures used for the classification of fungi? Select all the correct answers: a) Yeast b) Mold c) Mycelia d) Protozoa 3. Which of the following media is formulated with additional nutrients to support the growth of fastidious or nutritionally demanding bacteria that may not grow well on basic media? a) Differential media b) Enriched media c) Nutrient agar (media) d) Selective media 4. Which of the following metabolic characteristic is a distinguishing characteristic and identification of colonies of  E. coli ? a) Hydrogen sulfide formation b) Indole Formation c) Lactose fe...
3 comments
Read More

Multiple Choice Questions (MCQs) on Diabetes Mellitus: Pathogenesis, Diagnosis and Treatment

                                        MCQs on Diabetes mellitus 1) Diabetes mellitus is a disorder characterized by hyperglycemia.  Which of the following is not the common characteristic features of type 2 diabetes mellitus ? a) Impaired insulin secretion b) Increased Insulin resistance  c) Diabetic ketoacidosis d) Excessive hepatic glucose production 2) Which of the following are the characteristic features of type 1 diabetes mellitus? a) Type 1 diabetes is caused by an absolute deficiency of insulin. b) Type 1 diabetes is associated with the autoimmune destruction of beta cells.  c) Patients with  uncontrolled type 1 diabetes present with diabetic ketoacidosis d) All of the above   3) Which of the following serum measurements are not used for the diagnosis of diabetes mellitus? a) Fasting blood glucose d) Postprandial blood glucose  c) Insulin ...
5 comments
Read More